---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-072481"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T19:08:26.415303+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Q3 net loss narrows to $0.4M; revenue slides YoY; working capital insufficient

## Summary
- Q3 net revenues $4.9M, up 15% from Q2 but down YoY from $5.8M; nine-month revenues $12.5M vs $17.6M.
- Q3 net loss $0.4M ($0.01/shr) vs $3.2M loss in Q3 2021; operating loss $0.7M vs $31k.
- Cash and equivalents $1.2M vs $2.3M at Dec 31; working capital insufficient for next 12 months without restructuring.
- First Endari sales in UAE (approved May 2022) and early access in GCC countries boosted Q3 revenue.
- Company discussing restructuring or refinancing of indebtedness and other current liabilities.

## SEC filing metadata
- accession: 0001213900-22-072481
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/ea168520-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-072481
- JSON: https://secwatch.observer/filing/0001213900-22-072481.json
- Plain text: https://secwatch.observer/filing/0001213900-22-072481.txt

## Key facts
- Earnings Releases
  Emmaus Life Sciences, Inc. reported nine months ended September 30, 2022 results: revenue $12.5 million, net income a net loss of $10.8 million, EPS $0.22 per share.
  - Period: nine months ended September 30, 2022
  - Revenue: $12.5 million
  - Net income: a net loss of $10.8 million
  - EPS: $0.22 per share
  - Result: reported results
  source text: this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order purchases in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm
- Earnings Releases
  Emmaus Life Sciences, Inc. reported three months ended September 30, 2022 results: revenue $4.9 million, net income a net loss of $0.4 million, EPS $0.01 per share.
  - Period: three months ended September 30, 2022
  - Revenue: $4.9 million
  - Net income: a net loss of $0.4 million
  - EPS: $0.01 per share
  - Result: reported results
  source text: any transactions in this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.